GlassScriptPhysician profile
Ashley B Rountree
NPI 1447607056
$2,644.88
in general payments reported to CMS, 2019-2025
20 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.17 · 2022: $276 · 2023: $1,063 · 2024: $785 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.95 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $363.21 | 2022-2025 | Ozempic, Rybelsus |
| Inari Medical, INC. | $361.30 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $194.31 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $190.70 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $126.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bard Peripheral Vascular, INC. | $100.76 | 2023 | Venclose Maven Catheter |
| Glaxosmithkline, LLC. | $97.87 | 2023-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.29 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.38 | 2024-2025 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $50.16 | 2022-2023 | Contrave |
| Corcept Therapeutics | $37.04 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $25.92 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $18.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.17 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.56 | 2025 | Intellis Adaptivestim |
| Sumitomo Pharma America, INC. | $16.32 | 2024 | Gemtesa |
| Amgen INC. | $15.74 | 2024 | Repatha, Otezla |
| Viiv Healthcare Company | $15.01 | 2025 | Apretude |
| Astellas Pharma US INC | $13.58 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rountree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.